PH12023550119A1 - Egfr inhibitor - Google Patents

Egfr inhibitor

Info

Publication number
PH12023550119A1
PH12023550119A1 PH1/2023/550119A PH12023550119A PH12023550119A1 PH 12023550119 A1 PH12023550119 A1 PH 12023550119A1 PH 12023550119 A PH12023550119 A PH 12023550119A PH 12023550119 A1 PH12023550119 A1 PH 12023550119A1
Authority
PH
Philippines
Prior art keywords
egfr
egfr inhibitor
salt
general formula
active ingredient
Prior art date
Application number
PH1/2023/550119A
Other languages
English (en)
Inventor
Kei Oguchi
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Publication of PH12023550119A1 publication Critical patent/PH12023550119A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PH1/2023/550119A 2020-07-15 2021-07-14 Egfr inhibitor PH12023550119A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2020121525 2020-07-15
PCT/JP2021/026461 WO2022014639A1 (ja) 2020-07-15 2021-07-14 Egfr阻害剤

Publications (1)

Publication Number Publication Date
PH12023550119A1 true PH12023550119A1 (en) 2024-06-24

Family

ID=79554696

Family Applications (1)

Application Number Title Priority Date Filing Date
PH1/2023/550119A PH12023550119A1 (en) 2020-07-15 2021-07-14 Egfr inhibitor

Country Status (12)

Country Link
US (1) US20230285397A1 (https=)
EP (1) EP4197538A4 (https=)
JP (1) JP7495983B2 (https=)
KR (1) KR102873219B1 (https=)
CN (1) CN116368136B (https=)
AU (1) AU2021309779B2 (https=)
BR (1) BR112023000770A2 (https=)
CA (1) CA3189460A1 (https=)
MX (1) MX2023000693A (https=)
PH (1) PH12023550119A1 (https=)
TW (1) TW202216152A (https=)
WO (1) WO2022014639A1 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12492208B2 (en) * 2020-07-15 2025-12-09 Taiho Pharmaceutical Co., Ltd. Crystal of pyrimidine compound
EP4183395A4 (en) * 2020-07-15 2024-07-24 Taiho Pharmaceutical Co., Ltd. PYRIMIDINE COMPOUND-CONTAINING COMBINATION FOR USE IN TUMOR TREATMENT
JP2024520461A (ja) * 2021-05-24 2024-05-24 大鵬薬品工業株式会社 Egfr及び/又はher2に異常を有するがんを有する対象の治療方法
AU2024241633A1 (en) 2023-03-30 2025-11-06 Revolution Medicines, Inc. Compositions for inducing ras gtp hydrolysis and uses thereof
TW202508595A (zh) 2023-05-04 2025-03-01 美商銳新醫藥公司 用於ras相關疾病或病症之組合療法
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
TW202547461A (zh) 2024-05-17 2025-12-16 美商銳新醫藥公司 Ras抑制劑
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8426428B2 (en) 2008-12-05 2013-04-23 Principia Biopharma, Inc. EGFR kinase knockdown via electrophilically enhanced inhibitors
US9034885B2 (en) * 2012-01-13 2015-05-19 Acea Biosciences Inc. EGFR modulators and uses thereof
TW201336847A (zh) 2012-02-07 2013-09-16 Taiho Pharmaceutical Co Ltd 喹啉基吡咯并嘧啶化合物或其鹽
JP6141568B1 (ja) 2015-09-01 2017-06-07 大鵬薬品工業株式会社 新規なピラゾロ[3,4−d]ピリミジン化合物又はその塩
CA3015484C (en) * 2016-02-23 2022-11-08 Taiho Pharmaceutical Co., Ltd. Novel condensed pyrimidine compound or salt thereof
CA3121722C (en) * 2019-01-11 2024-01-16 Taiho Pharmaceutical Co., Ltd. Pyrimidine compound or salt thereof

Also Published As

Publication number Publication date
US20230285397A1 (en) 2023-09-14
KR102873219B1 (ko) 2025-10-17
JP7495983B2 (ja) 2024-06-05
BR112023000770A2 (pt) 2023-02-07
EP4197538A1 (en) 2023-06-21
JPWO2022014639A1 (https=) 2022-01-20
AU2021309779A1 (en) 2023-02-23
CN116368136B (zh) 2025-09-05
CA3189460A1 (en) 2022-01-20
MX2023000693A (es) 2023-02-13
AU2021309779B2 (en) 2024-06-27
WO2022014639A1 (ja) 2022-01-20
CN116368136A (zh) 2023-06-30
TW202216152A (zh) 2022-05-01
EP4197538A4 (en) 2024-08-07
KR20230026451A (ko) 2023-02-24

Similar Documents

Publication Publication Date Title
PH12023550119A1 (en) Egfr inhibitor
PH12021551529A1 (en) 3-carbonylamino-5-cyclopentyl-1h-pyrazole compounds having inhibitory activity on cdk2
ZA202204666B (en) 2-isoindol-1,3,4-oxadiazole derivatives useful as hdac6 inhibitors
GEAP202215535A (en) Compounds
CL2024000067A1 (es) Compuestos antivirales
SA521422143B1 (ar) 15-pgdh مثبط
PH12017502407A1 (en) Fused pyrimidine compound or salt thereof
NO20071719L (no) Pyridylinhibitorer for "hedgehog"-signalisering
DK2840080T3 (da) Nitrogenholdig heterocyklisk forbindelse eller salt deraf
AU2009258496A8 (en) Sulfur-containing heterocyclic derivative having beta-secretase-inhibiting activity
BRPI0412347A (pt) 2-aminofenil-4-fenilpiridinas como inibidores de quinase
TN2009000199A1 (en) Heteromonocyclic compound and use thereof
BR112012016111A2 (pt) Composto hererocíclico contendo nitrogênio, fungicida agrícola, e, produto intermediário
MX2008000255A (es) Activadores de urea glucocinasa.
JOP20230252A1 (ar) مشتقات فسفورية كمثبطات sos1 جديدة
MX2010008818A (es) Derivado de bicicloamina.
TW200510317A (en) Caspase inhibitors and uses thereof
MX2021013576A (es) Compuesto utilizado como inhibidor de la quinasa y aplicación del mismo.
PH12020551624A1 (en) Pyrazole compounds substituted with heteroaryl and pharmaceutical use thereof
MXPA05010440A (es) Amidas del acido isoquinolina-5-sulfonico como inhibidores de la akt (proteina quinasa b).
MY199779A (en) Pyrrolopyrimidine compound and use thereof
PH12021552513A1 (en) Pyrrole compounds
TN2021000025A1 (en) Novel heterocyclic amine derivative and pharmaceutical composition comprising same
PH12020552186A1 (en) Cyanotriazole compounds and uses thereof
MX391856B (es) Compuesto de pirrolopiridina novedoso, metodo de preparacion del mismo y uso del mismo